BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9607591)

  • 1. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
    Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A
    Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
    Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
    Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
    Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
    Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
    Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
    Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
    Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
    Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
    Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
    Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.
    Mohammad RM; Adsay NV; Philip PA; Pettit GR; Vaitkevicius VK; Sarkar FH
    Anticancer Drugs; 2001 Oct; 12(9):735-40. PubMed ID: 11593055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of c-myc in regulating mdr1 gene expression in tumor cell line KB.
    He Y; Zhang J; Zhang J; Yuan Y
    Chin Med J (Engl); 2000 Sep; 113(9):848-51. PubMed ID: 11776085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
    Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
    Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
    Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.